Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Gilead Sciences (GILD) Share Price
News coverage about Gilead Sciences (NASDAQ:GILD) has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Gilead Sciences earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.9594781801889 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Gilead Sciences, Inc.’s Best Investment of 2017 (Hint: It Wasn’t Kite Pharmaceuticals) (fool.com)
- Gilead Sciences, Inc. (GILD) 19.77% off from 200- SMA – Voice Of Analysts (analystsbuzz.com)
- Ex-Dividend Reminder: Gilead Sciences, Hill-Rom Holdings and Owens & Minor (nasdaq.com)
- How Gilead’s HCV Drugs Portfolio Performed in 2Q17 (finance.yahoo.com)
- How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17? (finance.yahoo.com)
Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.98% on Wednesday, reaching $83.68. 7,563,328 shares of the company’s stock traded hands. The company’s 50-day moving average price is $76.43 and its 200 day moving average price is $69.93. The firm has a market cap of $109.28 billion, a P/E ratio of 9.09 and a beta of 1.19. Gilead Sciences has a one year low of $63.76 and a one year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same period last year, the firm earned $3.08 EPS. On average, equities analysts forecast that Gilead Sciences will post $8.75 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.49%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
GILD has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Vetr raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price on the stock in a research report on Wednesday, September 6th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, July 27th. ValuEngine downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Eleven analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and an average target price of $83.06.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Gilead Sciences (GILD) Share Price” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-gilead-sciences-gild-share-price.html.
In related news, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the transaction, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 466,819 shares of company stock valued at $36,740,240. 1.30% of the stock is owned by insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.